San Diego-dependent Viking Therapeutics marked by itself as a significant competitor within the weight loss drug market in February after revealing promising data from the mid-phase trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when supplied as being a weekly injection As well as in March